Antiandrogens
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
N-acetylcys..
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Sotrovimab  COVID-19 treatment studies for Sotrovimab  C19 studies: Sotrovimab  Sotrovimab   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Metformin (meta)
Aspirin (meta) Molnupiravir (meta)
Bamlanivimab (meta) N-acetylcys.. (meta)
Bromhexine (meta) Nigella Sativa (meta)
Budesonide (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Povidone-Iod.. (meta)
Conv. Plasma (meta) Probiotics (meta)
Curcumin (meta) Proxalutamide (meta)
Ensovibep (meta) Quercetin (meta)
Favipiravir (meta) Remdesivir (meta)
Fluvoxamine (meta) Sotrovimab (meta)
Hydroxychlor.. (meta) Vitamin A (meta)
Iota-carragee.. (meta) Vitamin C (meta)
Ivermectin (meta) Vitamin D (meta)
Melatonin (meta) Zinc (meta)

Other Treatments Global Adoption
All Studies   All Outcomes
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Mortality 89% Improvement Relative Risk Mechanical ventilation 89% ICU admission 95% Hospitalization >24hrs.. 79% primary c19sv.com/gupta4.html Favors sotrovimab Favors control
4 December 2021 - Early treatment study
Early COVID-19 Treatment with SARS-CoV-2 Neutralizing Antibody Sotrovimab
Gupta et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofab466.701 (Peer Reviewed)
Source   PDF   Share   Tweet
RCT 1,057 outpatients, 529 treated with sotrovimab, showing significantly lower hospitalization and ICU admission with treatment. NCT04545060.
The preprint [1] for this study appears to show different results: 10, 6, 2 for ICU, ventilation, death, compared to 9, 4, 4 in this paper.
risk of death, 88.9% lower, RR 0.11, p = 0.12, treatment 0 of 528 (0.0%), control 4 of 529 (0.8%), NNT 132, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of mechanical ventilation, 88.9% lower, RR 0.11, p = 0.12, treatment 0 of 528 (0.0%), control 4 of 529 (0.8%), NNT 132, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of ICU admission, 94.7% lower, RR 0.05, p = 0.004, treatment 0 of 528 (0.0%), control 9 of 529 (1.7%), NNT 59, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of hospitalization >24hrs or death, 79.0% lower, RR 0.21, p < 0.001, treatment 6 of 528 (1.1%), control 30 of 529 (5.7%), NNT 22, day 29, ITT.
Effect extraction follows pre-specified rules prioritizing more serious outcomes.
Conflicts of interest: research funding from the drug patent holder, employee of the drug patent holder.
Gupta et al., 12/4/2021, Double Blind Randomized Controlled Trial, multiple countries, multiple regions, peer-reviewed, 22 authors.
All Studies   All Outcomes
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. WCH and FLCCC provide treatment protocols.
  or use drag and drop   
Submit